Sartorius Stedim Biotech S.A. (LON:0RG8)
London
· Delayed Price · Currency is GBP · Price in EUR 203.87
-4.73 (-2.27%)
At close: Feb 21, 2025
Sartorius Stedim Biotech Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 2,780 | 2,776 | 3,493 | 2,887 | 1,910 | Upgrade
|
| Revenue Growth (YoY) | 0.16% | -20.53% | 20.98% | 51.15% | 32.59% | Upgrade
|
| Cost of Revenue | 1,573 | 1,542 | 1,675 | 1,334 | 906.76 | Upgrade
|
| Gross Profit | 1,207 | 1,234 | 1,817 | 1,553 | 1,003 | Upgrade
|
| Selling, General & Admin | 650.1 | 617.6 | 612.3 | 531.9 | 391.85 | Upgrade
|
| Research & Development | 144.1 | 129.5 | 132.4 | 110.5 | 84.45 | Upgrade
|
| Other Operating Expenses | 16.5 | 17.5 | 18.2 | -9.6 | 23.89 | Upgrade
|
| Operating Expenses | 810.7 | 764.6 | 762.9 | 632.8 | 500.19 | Upgrade
|
| Operating Income | 396 | 469.4 | 1,054 | 920.2 | 503.14 | Upgrade
|
| Interest Expense | -148 | -115.4 | -18.2 | -10.2 | -6.51 | Upgrade
|
| Interest & Investment Income | 18.9 | 6.2 | 0.5 | 0.3 | 0.51 | Upgrade
|
| Earnings From Equity Investments | -8.6 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 6.6 | -13.3 | -32.8 | 12.3 | -14.66 | Upgrade
|
| Other Non Operating Income (Expenses) | -12.9 | -4.3 | -4.6 | -37.1 | 1.08 | Upgrade
|
| EBT Excluding Unusual Items | 252 | 342.6 | 999.3 | 885.5 | 483.55 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -20.3 | -4.3 | Upgrade
|
| Other Unusual Items | -32.8 | 59.3 | 131.1 | -218.5 | -18.56 | Upgrade
|
| Pretax Income | 219.2 | 401.9 | 1,130 | 646.7 | 460.69 | Upgrade
|
| Income Tax Expense | 40.7 | 89.2 | 250.5 | 232.4 | 122.1 | Upgrade
|
| Earnings From Continuing Operations | 178.5 | 312.7 | 879.9 | 414.3 | 338.6 | Upgrade
|
| Minority Interest in Earnings | -3.4 | -2.4 | -3.8 | 0.1 | -2.67 | Upgrade
|
| Net Income | 175.1 | 310.3 | 876.1 | 414.4 | 335.93 | Upgrade
|
| Net Income to Common | 175.1 | 310.3 | 876.1 | 414.4 | 335.93 | Upgrade
|
| Net Income Growth | -43.57% | -64.58% | 111.41% | 23.36% | 43.25% | Upgrade
|
| Shares Outstanding (Basic) | 97 | 92 | 92 | 92 | 92 | Upgrade
|
| Shares Outstanding (Diluted) | 97 | 92 | 92 | 92 | 92 | Upgrade
|
| Shares Change (YoY) | 5.01% | -0.00% | -0.01% | -0.00% | 0.00% | Upgrade
|
| EPS (Basic) | 1.81 | 3.37 | 9.51 | 4.50 | 3.64 | Upgrade
|
| EPS (Diluted) | 1.81 | 3.37 | 9.51 | 4.50 | 3.64 | Upgrade
|
| EPS Growth | -46.26% | -64.58% | 111.45% | 23.51% | 43.31% | Upgrade
|
| Free Cash Flow | 475.3 | 272.8 | 181.7 | 377.9 | 257.69 | Upgrade
|
| Free Cash Flow Per Share | 4.91 | 2.96 | 1.97 | 4.10 | 2.80 | Upgrade
|
| Dividend Per Share | 0.690 | 0.690 | 1.440 | 1.260 | 0.680 | Upgrade
|
| Dividend Growth | 0% | -52.08% | 14.29% | 85.29% | 100.00% | Upgrade
|
| Gross Margin | 43.41% | 44.46% | 52.03% | 53.79% | 52.53% | Upgrade
|
| Operating Margin | 14.24% | 16.91% | 30.19% | 31.87% | 26.34% | Upgrade
|
| Profit Margin | 6.30% | 11.18% | 25.08% | 14.35% | 17.59% | Upgrade
|
| Free Cash Flow Margin | 17.10% | 9.83% | 5.20% | 13.09% | 13.49% | Upgrade
|
| EBITDA | 629.3 | 657.7 | 1,197 | 1,031 | 577.32 | Upgrade
|
| EBITDA Margin | 22.64% | 23.70% | 34.27% | 35.73% | 30.22% | Upgrade
|
| D&A For EBITDA | 233.3 | 188.3 | 142.5 | 111.2 | 74.18 | Upgrade
|
| EBIT | 396 | 469.4 | 1,054 | 920.2 | 503.14 | Upgrade
|
| EBIT Margin | 14.24% | 16.91% | 30.19% | 31.87% | 26.34% | Upgrade
|
| Effective Tax Rate | 18.57% | 22.19% | 22.16% | 35.94% | 26.50% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.